$CELG (Celgene Corporation)

$CELG {{ '2016-07-28T13:13:20+0000' | timeago}} • Announcement

$CELG now sees 2016 total product sales of about $11Bil compared to prior forecast of $10.75-11Bil. The company lowered its 2016 GAAP EPS guidance to $3.82-4.05 from prior range of $4.26-4.56, while lifting its adjusted EPS outlook to $5.70-5.75 from $5.60-5.70. $CELG also cut weighted average diluted shares forecast to 806MM from 811MM.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$CELG {{ '2017-12-11T14:27:28+0000' | timeago}} • Announcement

$CELG and $JUNO report additional data from the TRANSCEND study. Celgene added that the results of this study show the potential for the CAR T therapy, a therapy to treat cancers. Application filing is expected to be completed in 2H18, with approval as early as the end of 2018. In June 2015, Celgene partnered with Juno Therapeutics by paying $1Bil.

$CELG {{ '2017-12-11T13:33:44+0000' | timeago}} • Announcement

$CELG and its partner $BLUE announce results of Phase I study of bb2121, a therapy that is jointly developed by both the companies for treating blood cancer. Of the 18 patients enrolled for this trial, 56% achieved complete response and only one patient (6%) didn't respond to the treatment.

$CELG {{ '2017-11-16T14:30:32+0000' | timeago}} • Announcement

$CELG and its partner $BLUE reported that FDA granted Breakthrough Therapy Designation, which will expedite the review of the plasma cell cancer treating therapy. This was based on the preliminary data from the ongoing phase 1 study of the therapy. In March 2013, Celgene and Bluebird Bio entered into a strategic alliance in the field of oncology.

$CELG {{ '2017-10-31T16:07:34+0000' | timeago}} • Announcement

In a confidential license agreement, $CELG and $LCI enter into a settlement related to Celgene's Thalomid drug, which is used to treat the plasma cell cancer. This agreement allows Lannett to manufacture and market a generic thalidomide product in the US from Aug. 1, 2019, or earlier under certain circumstances.

$CELG {{ '2017-10-30T23:17:02+0000' | timeago}} • Announcement

$CELG cut down its FY17 GAAP EPS outlook from $5.36-5.62 range to $4.78-5.19 range. For FY20, the drugmaker slashed its total net product sales target from the previous target of greater than $21Bil to $19-20Bil range and adjusted EPS target was reduced from the previous target of greater than $13 to greater than $12.50.

$CELG {{ '2017-10-30T22:55:16+0000' | timeago}} • Announcement

Despite higher profit and revenues in 3Q17, $CELG cut down its outlook for 2017 and 2020. Profit spiked nearly six times to $988MM or $1.21 per share, while revenue rose 10% to $3.29Bil. Product sales were up 11% to $3.28Bil, helped by the increase in sales of Revlimid, Pomalyst/Imnovid, Otezla and Abraxane drugs.

$CELG {{ '2017-10-26T12:55:41+0000' | timeago}} • Infographic

$CELG Celgene Corp. Earnings AlphaGraphic: Q3 2017 Highlights

$CELG {{ '2017-10-20T12:40:12+0000' | timeago}} • Announcement

$CELG disclosed in an SEC filing that it expects to incur a pretax charge to earnings for 4Q17 in the range of $300-500MM ($0.27-0.45 per diluted share after tax) in connection with its decision to stop the two trials for Crohn's disease. Celgene also added that it would require to pay half of this charge in cash.

$CELG {{ '2017-10-19T21:12:44+0000' | timeago}} • Announcement

$CELG said that it will stop the two trials for treating the Crohn's disease (a chronic inflammatory bowel disease), following the recommendation of the Data Monitoring Committee. No safety signals were identified during a recent interim futility analysis. Celgene added that the third trial will not be initiated at this time.

$CELG {{ '2017-09-19T18:41:27+0000' | timeago}} • Announcement

After collaborating with $CELG for almost a decade, $XLRN amended its development and commercial agreement with Celgene for the investigational drug Sotatercept. Acceleron will develop and market Sotatercept in the pulmonary hypertension field. Celgene will be eligible to receive royalties on global net sales in that field.

$CELG {{ '2017-09-08T15:34:27+0000' | timeago}} • Announcement

$CELG to present data from multiple studies about the use of Abraxane to treat non-small lung cancer and pancreatic cancer. The data will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting between Sept 8-12 in Madrid, Spain.

$CELG {{ '2017-09-07T15:10:29+0000' | timeago}} • Announcement

$CELG gets a pause from FDA as it partially holds the drugmaker's five clinical trials and one clinical trial fully. All of these trials involve cancer drug Durvalumab. Celgene added that patients enrolled in the partial hold trials may remain on the treatment and those who are on full clinical hold trial will be discontinued from the treatment.

$CELG {{ '2017-08-01T17:51:34+0000' | timeago}} • Announcement

$CELG and $AGIO said Idhifa (enasidenib) was granted approval from FDA for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 mutation. The approval was based on results from the Phase I/II study. AML is a cancer of blood and bone marrow marked by rapid disease progression.

$CELG {{ '2017-07-27T19:16:33+0000' | timeago}} • Announcement

For FY17, $CELG cut down its GAAP EPS outlook to $5.36-5.62 from its prior estimate of $5.95-6.29. However, Celgene lifted its non-GAAP EPS outlook to $7.25-7.35 from its previous estimate of $7.15-7.30. The company didn't alter its previous revenue outlook of $13.0-13.4Bil.

$CELG {{ '2017-07-27T18:53:16+0000' | timeago}} • Announcement

Biotech heavyweight $CELG reported strong profit in 2Q17, helped by higher product sales. Net income of $1.06Bil and diluted EPS of $1.31, surged 77% and 75%, respectively. Total revenue rose 19% to $3.3Bil, while  net product sales alos increased 19% for the recent quarter. Celgene's earnings grew 26% to $1.82 per share on an adjusted basis.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$CELG {{ '2017-07-25T20:43:29+0000' | timeago}} • Announcement

$CELG, which is set to release its earnings results on July 27, settles a lawsuit filed by Beverly Brown, a former saleswoman of the drugmaker, by paying a total of $280MM. The lawsuit claimed that Celgene used illegal marketing tactics to promote its cancer drugs Thalomid and Revlimid among doctors.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
ARQL (ArQule Inc.)
Thursday, November 9 2017 - 2:00pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
ATHX (Athersys, Inc.)
Wednesday, November 8 2017 - 9:30pm
VCEL (Vericel Corporation)
Tuesday, November 7 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
EXEL (Exelixis, Inc.)
Wednesday, November 1 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
ARRY (Array BioPharma Inc.)
Tuesday, October 31 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 8:30pm
ATHX (Athersys, Inc.)
Wednesday, August 9 2017 - 8:30pm

AlphaGraphics you may like